Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 129

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 129
---
 to market, and the change in fair value of the derivative was recorded as a (loss)/gain of $(53,257) and $148,751, in the years ended December 31, 2024 and 2023, respectively.

Gain (Loss) on Extinguishment of Debt

During the years ended 2024 and 2023, the Senior Secured Convertible Note was amended several times with materially different economics thus requiring for the recording of debt as an extinguishment and re-recording the debt with the amended terms. This resulted in a gain/(loss) on extinguishment of debt in the years ended December 31, 2024 and 2023 of $857,723 and $(887,946), respectively.

| 72 |

Liquidity and Capital Resources; Plan of Operations

As of September 30, 2025 and December 31, 2024, we had cash and cash equivalents of $723,797 and $3,769,510, respectively. Our cash equivalents are held in high yield savings account. We have generated no product sales since our inception and have negative cash flows from operations. We incurred net losses of $6,069,866 for the nine months ended September 30, 2025 and $2,439,625 and $4,783,689 for the fiscal years ended December 31, 2024 and 2023, respectively.

We had an accumulated deficit of $32,091,995 as of September 30, 2025.

Historically, we have financed our operations primarily by selling common stock and convertible debt. On December 2, 2024, the Company priced its initial public offering of 2,750,000 shares of common stock at a price of $4.00 per share. The offering closed on December 4, 2024, and the Company started trading on the Nasdaq under the ticker symbol “JUNS”. The Company sold 2,750,000 shares of its common stock to the underwriters and yielded proceeds of $9,725,213, net of underwriters and other fees of $1,274,787. On April 11, 2022, we issued a senior secured convertible note in the principal amount of $1,111,111 in exchange for $1,000,000, which was paid down with the proceeds from initial public offering.

We have generated no revenues from product sales since inception, incurred a net loss of $6,069,866 for